Pharmacological Reviews Get Tables of Contents delivered automatically
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kalow, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kalow, W.

Vol. 49, Issue 4, 369-380, December 1997

Pharmacogenetics in Biological Perspective

W. Kalowa

Department of Pharmacology, University of Toronto, Toronto, Ontario, Canada

I. Introduction
II. The Word "Pharmacogenetics"
III. The Nature of Examples
    A. Human Data
        1. Pharmacokinetic compared with pharmacodynamic variation.
        2. The example of debrisoquine hydroxylase deficiency.
        3. Epidemiological implications of kinetic variants.
    B. Toxicant Resistance in Arthropods and Bacteria
        1. Arthropods.
        2. Bacteria.
IV. Comparing Intoxication and Infectious Disease
V. The Biological Cost of Variation
VI. Quantitative Aspects of Pharmacogenetic Variation
    A. Monogenic Variation
    B. Gaussian Variation
VII. Pharmacogenetics and Evolution
VIII. Summary and Conclusions
Acknowledgments
References

a   Address for correspondence: Dr. W. Kalow, Department of Pharmacology, Medical Sciences Building, University of Toronto, Toronto, Ontario M5S 1A8, Canada.

0031-6997/97/4904-0369$03.00/0
PHARMACOLOGICAL REVIEWS
Copyright © 1997 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Science Technology Human ValuesHome page
A. M. Hedgecoe
Terminology and the Construction of Scientific Disciplines: The Case of Pharmacogenomics
Science Technology Human Values, October 1, 2003; 28(4): 513 - 537.
[Abstract] [PDF]

Home page
 NeurologyHome page
M. Zappia, G. Annesi, A. Quattrone, J. Wang, Z.-L. Liu, and B. Chen
Association study of dopamine D2, D3 receptor gene polymorphisms with motor fluctuations in PD
Neurology, March 12, 2002; 58(5): 837 - 838.
[Full Text] [PDF]

Home page
 J Law Med EthicsHome page
L. F. Ross
Genetic Exceptionalism vs. Paradigm Shift: Lessons from HIV
J. Law Med. Ethics, June 1, 2001; 29(2): 141 - 148.
[PDF]

Home page
 Drug Metab. Dispos.Home page
M. T. Cronin, M. Pho, D. Dutta, F. Frueh, L. Schwarcz, and T. Brennan
Utilization of New Technologies in Drug Trials and Discovery
Drug Metab. Dispos., April 1, 2001; 29(4): 586 - 590.
[Abstract] [Full Text]

Home page
 J Law Med EthicsHome page
L. F. Ross
Genetic Exceptionalism vs. Paradigm Shift: Lessons from HIV
J. Law Med. Ethics, March 1, 2001; 29(1): 141 - 148.
[PDF]

Home page
 NeurologyHome page
R. L. Oliveri, G. Annesi, M. Zappia, D. Civitelli, R. Montesanti, D. Branca, G. Nicoletti, P. Spadafora, A. A. Pasqua, R. Cittadella, et al.
Dopamine D2 receptor gene polymorphism and the risk of levodopa-induced dyskinesias in PD
Neurology, October 22, 1999; 53(7): 1425 - 1425.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
D. G.B. Leonard
The Future of Molecular Genetic Testing
Clin. Chem., May 1, 1999; 45(5): 726 - 731.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
R. E. Pratt and V. J. Dzau
Genomics and Hypertension : Concepts, Potentials, and Opportunities
Hypertension, January 1, 1999; 33(1): 238 - 247.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition